For the month ended 31 May 2026, China Biotech Services Holdings Limited reported no changes to either its authorised or issued share capital. Authorised capital remains at 2.00 billion ordinary shares with a par value of HK$0.10, equivalent to HK$200.00 million. Issued shares were steady at 975.73 million, and the company held no treasury shares. Management confirmed compliance with the Hong Kong Stock Exchange’s 25% minimum public-float requirement.

Convertible bonds constitute the sole potential source of future dilution:

1) 2024 Convertible Bonds: US$6.00 million in principal, convertible at HK$1.11 per share, allowing for up to 42.43 million new shares. Maturity is 27 December 2026.

2) 2026 Convertible Bonds: US$35.00 million in principal, convertible at HK$0.66 per share, enabling up to 412.58 million new shares. Maturity is 20 February 2030.

Cumulatively, full conversion of both tranches would expand the current share base by approximately 46.65%, adding 455.01 million shares to the 975.73 million outstanding.

The company reported no share option grants, warrant issues, share repurchases, or other equity movements during the month.